SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS

INTRODUCTION: Mismatch repair (MMR) deficiency through MSH6 inactivation has been identified in approximately 25% of recurrent gliomas. This MMR deficiency represents a key molecular mechanism of acquired resistance to the alkylating chemotherapeutic agent temozolomide (TMZ). Potentiation of TMZ-ind...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neurooncol Adv
Autores principales: Higuchi, Fumi, Nagashima, Hiroaki, Wakimoto, Hiroaki, Daniel P, Cahill
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213165/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.031
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares